New research suggests that eating too much cheese or other dairy before bed is linked to more bad dreams

Cases of the chikungunya virus, transmitted by mosquitoes, are rising worldwide, raising health concerns. Symptoms include fever and severe joint pain.

Editor’s Note: The surge in chikungunya cases highlights the need for increased awareness and preventive measures against mosquito-borne diseases, which can significantly impact public health.

Kentucky Governor Andy Beshear has banned the sale of a synthetic drug called 'designer Xanax' in the state, taking emergency action to protect public health.

Editor’s Note: This ban is significant as it reflects a growing concern among state leaders about the dangers of synthetic drugs. By taking this step, Governor Beshear aims to safeguard the community and set a precedent for other states facing similar issues.

Wildfire fighters in the U.S. are facing serious health risks as they are often sent into toxic smoke without proper protective gear. This negligence has led to illnesses and fatalities among the crews.

Editor’s Note: This issue highlights the urgent need for better safety measures for wildfire fighters. As climate change increases the frequency and intensity of wildfires, ensuring the health and safety of those who combat these fires is crucial.

New research indicates that consuming cheese or other dairy products before bedtime may lead to an increase in bad dreams, particularly for those who are lactose intolerant.

Editor’s Note: This study highlights the impact of diet on sleep quality, suggesting that certain foods can negatively affect our dreams. Understanding these connections can help people make better dietary choices for improved sleep.

Parents of children with Barth syndrome are urging the FDA to approve Elamipretide, a drug that shows promise in treating this rare and fatal disease. Current options are limited, and the denial of approval leaves families in a difficult situation.

Editor’s Note: This situation highlights the urgent need for effective treatments for rare diseases. The FDA's decision impacts not only the children suffering from Barth syndrome but also raises questions about the approval process for drugs targeting ultrarare conditions.